Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: Two-year clinical trial data

Type 1 Diabetes TrialNet ATG-GCSF Study Group

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint Dive into the research topics of 'Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA<sub>1c</sub>, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: Two-year clinical trial data'. Together they form a unique fingerprint.

Medicine & Life Sciences